BTD

Across TCGA pan-cancer cohorts, BTD mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated BTD data layer compared with 17 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher BTD mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated BTD expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

LUAD, CCRCC, and PDAC are the cancer types where BTD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	II,III,IV	0.618	1.000	.005	30	view →
CCRCC	OS	Median	IV	0.785	0.123	.009	16	view →
PDAC	DFS	Tertile	III,IV	0.153	0.524	.012	15	view →
HNSC	DFS	Tertile	III,IV	1.000	0.872	.010	5	view →
LSCC	DFS	Median	All	0.875	0.992	.017	4	view →
UCEC	DFS	Median	All	0.925	0.778	.012	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

BTD–LUAD (DFS)

Open the LUAD breakdown →